COMPLEMENT THERAPEUTICS

• 72110 - Research and experimental development on biotechnology

Complement Therapeutics is a spin-out from The University of Manchester. Its founders have international reputations and world-leading Complement System expertise... Our immediate focus with our lead asset CTx001 is the treatment of Geographic Atrophy (late dry age-related macular degeneration), where no licensed treatment is currently available. CTx001 is in pre-clinical development as an AAV based gene therapy for the targeted treatment of Geographic Atrophy. Harnessing the benefits of gene therapy and our unique mechanism of action, CTx001 has the potential to transform the lives of people living with GA... In addition, we are developing therapeutics that are aimed at systemic modulation of the complement system. We anticipate that these assets will meet the needs of a wide range of patients with complement-mediated disease.

Also known as: Complement Therapeutics GmbH, COMPLEMENT THERAPEUTICS LIMITED, Complement Therapeutics Ltd

Registration numbers: 12515463 (CH)

Primary location: London United Kingdom